<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973749</url>
  </required_header>
  <id_info>
    <org_study_id>C13-17</org_study_id>
    <nct_id>NCT03973749</nct_id>
  </id_info>
  <brief_title>Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD</brief_title>
  <acronym>AERD</acronym>
  <official_title>Effects of a High or Low Salycilate Diet on Urinary Leucotriene E4 Levels and Clinical Features in Patients With Aspirin Exacerbated Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Enfermedades Respiratorias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      On day one, two groups of nine patients each will respectively recieve the tree daily meals
      (breakfast, Lunch and dinner) in a controled clinical setting. Group 1 will recieve a
      low-salycilate diet, and group 2 a high-salycilate diet. Two hours after each meal, urinary
      Leucotriene E4, FEV1, FVC, FEV1/FVC and total nasal resistance will be measured. On day 7,
      after clearance time, group 1 will recieve high-salycilate diet and group 2 low salycilate
      diet and the same measurements will be obtained.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Urinary concentration of Leucotriene E4 (LTE4)</measure>
    <time_frame>Baseline-4-8-12 hours in day one and Baseline-4-8-12 hours in day 7</time_frame>
    <description>pg/ml of creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Expiratory Volume in 1 second (FEV-1)</measure>
    <time_frame>Baseline-4-8-12 hours and Baseline-4-8-12 hours in day 7</time_frame>
    <description>Percentage of referenced value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Vital Capacity (FVC)</measure>
    <time_frame>Baseline-4-8-12 hours and Baseline-4-8-12 hours in day 7</time_frame>
    <description>Percentage of referenced value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Relationship between FEV1/FVC</measure>
    <time_frame>Baseline-4-8-12 hours and Baseline-4-8-12 hours in day 7</time_frame>
    <description>Percentage of referenced value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the total nasal resistance obtained by rhinometry</measure>
    <time_frame>Baseline-4-8-12 hours and Baseline-4-8-12 hours in day 7</time_frame>
    <description>pascals/cm3/sec</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Aspirin-exacerbated Respiratory Disease</condition>
  <condition>Aspirin-Sensitive Asthma With Nasal Polyps</condition>
  <condition>Samter's Syndrome</condition>
  <condition>Widal Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low salycilate diet on day one and High salycilate diet on day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High salycilate diet on day one and Low salycilate diet on day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low salycilate diet</intervention_name>
    <description>Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>High salycilate diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed Aspirin exacerbated respiratory disease.

          -  Controled asthma

          -  No actual systemic corticosteroid treatment

          -  No antileucotriene treatment.

        Exclusion Criteria:

          -  Patients who do not complete both phases of the study

          -  Patients unable to perform adecuate spyrometric testing

          -  Patients who present severe asthmatic reactions with high salycilate foods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias</name>
      <address>
        <city>Mexico City</city>
        <state>Ciudad DE Mexico</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Enfermedades Respiratorias</investigator_affiliation>
    <investigator_full_name>Marcos Alejandro Jimenez Chobillon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

